Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis.

Drug Des Devel Ther · 2023 · PMC10024496 · PMID 36942304

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

6 However, imatinib shows a decreasing trend in bioavailability after repeated dosing, and one month after the first dose, the bioavailability of imatinib decreases by about 17%. 7 Imatinib binds approximately 95% to plasma proteins, mainly plasma albumin, followed by alpha-acidic glycoprotein; a small fraction binds to lipoproteins.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.